Neovascular Age-related Macular Degeneration
Conditions
Keywords
PMC-403
Brief summary
This is a Phase 1 study, first-in-human (FIH), open label study to evaluate the safety, tolerability and identify the maximum tolerated dose (MTD) of PMC-403 and determine the recommended phase 2 dose (RP2D).
Detailed description
In this study, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) will be carried out in a sequential manner. \- PART 1- SAD The SAD part of the study will be conducted in a step-wise manner for a total of 4 dose levels (0.7 mg, 2 mg, 3 mg, 4 mg). To each dose group, 3 subjects at minimum or 6 subjects at maximum will be recruited. In the SAD part, dose escalation will be performed up to 4 mg/eye (50 uL/eye) until the MTD is identified. In the SAD part, a maximum of 24 participants are to be enrolled. \- PART 2- MAD Upon the end of the SAD part of the study, the MAD part is planned to be conducted in a step-wise manner for a total of 2 dose levels (3 mg, 4 mg). In the MAD part will begin with dose level 1 (3 mg). Subjects will be given a total of 3 doses of IP at 4-week intervals over a total period of 12 weeks and will be assessed for safety and tolerability according to study procedures. While a total of 6 subjects are to be recruited per dose group in the MAD part. Dose escalation will be performed up to 4 mg/eye (50 uL/eye) until the MTD is identified. In the MAD part, a maximum of 12 participants are to be enrolled.
Interventions
DRUGPMC-403
PMC-403 will be administered Intravitreal.
Sponsors
C&R Research, Inc.
PharmAbcine
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
To be eligible for study participation, subjects must meet all of the following inclusion criteria. \* Criteria for the selection of the study eye If both eyes meet the criteria, the study eye will be selected according to the following criteria: 1. The eye with lower (severer) best corrected visual acuity (BCVA) at baseline will be selected as the study eye. 2. If both eyes have the same BCVA, the right eye will be selected as the study. 1. Male and female ≥50 years of age at the time of written informed consent. 2. Treatment required, based on the judgment of the investigator, due to insufficient therapeutic efficacy despite ≥ 3 repeated doses of anti-vascular endothelial growth factor (anti-VEGF) intravitreal injection (IVT) for nAMD in the study eye, and the subject's agreement to receive the study drug instead of conventional standard therapy 3. \>12 weeks must have elapsed since the last dose of anti-VEGF IVT at the time of screening. 4. Active subfoveal or parafoveal choroidal neovascularization (CNV)\* confirmed by fundus fluorescein angiography (FFA), spectral domain-optical coherence tomography (SD-OCT), and IndoCyanine Green (ICG) angiography. \*Active CNV (confirmed by the central reading center) is defined as the presence of subretinal fluid (SRF) or intraretinal fluid (IRF) in consequence of vascular leakage. 5. The size of the entire lesion in the study eye (including blood, atrophy, fibrosis, and neovascularization) must be ≤ 9-disc areas, and the area of CNV in the study eye must account for ≥ 50% of the total area of the lesion, as confirmed by FFA and ICG angiography. 6. BCVA measured in the study eye must be between ≥ 23 letters and ≤ 78 letters based on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart (Snellen visual acuity 20/25 - 20/320). 7. Voluntary written informed consent to study participation.
Exclusion criteria
Subjects who meet any of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Laboratory tests - Blood chemistry | Baseline upto 5 months | Blood chemistry will be performed at Visits 1, 2, 5, and 7 and at Follow-up Visits 8 and 9 in the SAD groups and at each visit in the MAD groups. The following Blood chemistry parameters will be recorded: glucose, aspartate transaminase (AST; SGOT), alanine transaminase (ALT; SGPT), total bilirubin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total protein, albumin, blood urea nitrogen (BUN), creatinine, uric acid, sodium, potassium, chloride, calcium, phosphorus, C-reactive protein (CRP), HbA1c (to be tested at the screening visit only) Test results collected will be assessed for change before and after IP dosing and/or change in normal/abnormal findings. |
| Maximum tolerated dose (MTD) | Baseline upto 4 weeks | To identify the maximum tolerated dose (MTD), and determine the recommended phase 2 dose (RP2D) of PMC-403 in patients with nAMD. MTD of PMC-403 will be calculated by incidence of DLT at 4 weeks from the first dosing of PMC-403. |
| Adverse events | Baseline upto 5 months | For Treatment-emergent adverse events (TEAEs), Adverse Drug Reactions (ADRs), Serious Adverse Events (SAEs), Serious Adverse Drug Reactions (SADRs), and Adverse Events (AEs) leading to study withdrawal, number of subjects, incidence, number of events, and 95% two-sided confidence interval will be presented by dose group. |
| Vital Signs - Pulse Rate (beats/min) | Baseline upto 5 months | At each visit, pulse rate will be measured. Vital signs collected will be assessed for change before and after IP dosing and/or change in normal/abnormal findings. By dose group, values at each time point will be presented with number of subjects, mean, standard deviation, median, minimum, and maximum; and change from baseline at each time point will be presented with number of subjects, mean, standard deviation, median, minimum, and maximum. |
| Vital Signs - body temperature | Baseline upto 5 months | At each visit, body temperature will be measured. Vital signs collected will be assessed for change before and after IP dosing and/or change in normal/abnormal findings. By dose group, values at each time point will be presented with number of subjects, mean, standard deviation, median, minimum, and maximum; and change from baseline at each time point will be presented with number of subjects, mean, standard deviation, median, minimum, and maximum. |
| Vital Signs - systolic/diastolic blood pressure (mmHg) | Baseline upto 5 months | At each visit, systolic/diastolic blood pressure will be measured. Vital signs collected will be assessed for change before and after IP dosing and/or change in normal/abnormal findings. By dose group, values at each time point will be presented with number of subjects, mean, standard deviation, median, minimum, and maximum; and change from baseline at each time point will be presented with number of subjects, mean, standard deviation, median, minimum, and maximum. |
| Laboratory tests - Hematology | Baseline upto 5 months | Hematology will be performed at Visits 1, 2, 5, and 7 and at Follow-up Visits 8 and 9 in the SAD groups and at each visit in the MAD groups. The following Hematology parameters will be recorded: white blood cell (WBC), red blood cell (RBC), hemoglobin, hematocrit, platelet, WBC differential count (neutrophil, lymphocyte, monocyte, eosinophil, basophil) Test results collected will be assessed for change before and after IP dosing and/or change in normal/abnormal findings. |
| Laboratory tests - Urinalysis | Baseline upto 5 months | Urinalysis will be performed at Visits 1, 2, 5, and 7 and at Follow-up Visits 8 and 9 in the SAD groups and at each visit in the MAD groups. For continuous variables, values at each time point will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum; and change from baseline at each time point will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. Additionally, test results collected will be assessed for change before and after IP dosing and/or change in normal/abnormal findings. |
| Ophthalmologic examination - intraocular pressure (IOP) | Baseline upto 5 months | IOP will be performed according to Schedule of Events. During the study visits involving IP dosing (SAD: Visits 2, MAD: Visits 2, 5, 7), IOP will be measured a total of 3 times (once before dosing and twice after dosing). For continuous variables, values at each time point will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. The ophthalmologic examination results will be assessed for change in normal/abnormal status before and after IP dosing. |
| Ophthalmologic examination - spectral domain-optical coherence tomography (SD-OCT) | Baseline upto 5 months | SD-OCT will be performed according to Schedule of Events. For continuous variables, values at each time point will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. The ophthalmologic examination results will be assessed for change in normal/abnormal status before and after IP dosing. |
| Ophthalmologic examination - fundus examination | Baseline upto 5 months | fundus examination measuring will be performed according to Schedule of Events. For continuous variables, values at each time point will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. The ophthalmologic examination results will be assessed for change in normal/abnormal status before and after IP dosing. |
| Ophthalmologic examination - Slit lamp examination | Baseline upto 5 months | Slit lamp examination measuring will be performed according to Schedule of Events. For continuous variables, values at each time point will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. The ophthalmologic examination results will be assessed for change in normal/abnormal status before and after IP dosing. |
| Electrocardiogram (ECG) | Baseline upto 5 months | Test results will be classified into normal/NCS and CS, and change from baseline at each time point and at the last visit will be presented with frequency and percentage in a shift table by dose group. The following ECG parameters will be recorded: heart rate, RR interval, HR interval, QTc interval and QRS interval. |
| Laboratory tests - Blood coagulation | Baseline upto 5 months | Blood coagulation will be performed at Visits 1, 2, 5, and 7 and at Follow-up Visits 8 and 9 in the SAD groups and at each visit in the MAD groups. For continuous variables, values at each time point will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum; and change from baseline at each time point will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. Additionally, test results collected will be assessed for change before and after IP dosing and/or change in normal/abnormal findings. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in CNV lesion size as measured by ICG angiography | Baseline upto 5 months | ICG angiography will be performed to measure the size of CNV lesions and to assess vascular leakage. For CNV lesion size will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum; and change from baseline at each time point will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. |
| Change in best corrected visual acuity (BCVA) | Baseline upto 5 months | It is measured by early treatment of diabetic retinopathy study (ETDRS) chart at each point of visit. For BCVA will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum; and change from baseline at each time point will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. |
| Change in central retinal thickness (CRT) | Baseline upto 5 months | It is measured by SD-OCT at each point of visit. For CRT will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum; and change from baseline at each time point will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. |
| Presence of intraretinal fluid (IRF) | Baseline upto 5 months | It is measured by SD-OCT at each point of visit. For presence of IRF frequency, percentage, and 95% confidence interval will be presented by dose group. |
| Presence of subretinal fluid (SRF) | Baseline upto 5 months | It is measured by SD-OCT at each point of visit. For presence of SRF frequency, percentage, and 95% confidence interval will be presented by dose group. |
| Presence of sub-RPE fluid | Baseline upto 5 months | It is measured by SD-OCT at each point of visit. For presence of sub-RPE fluid frequency, percentage, and 95% confidence interval will be presented by dose group. |
| Change from baseline in choroidal neovascularization (CNV) lesion size as measured by Fundus Fluorescein Angiography (FFA) | Baseline upto 5 months | FFA will be performed to measure the size of CNV lesions and to assess vascular leakage. For CNV lesion size will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum; and change from baseline at each time point will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic parameters - Area under the blood concentration-time curve (AUC) | Baseline upto 5 months | Area under the blood concentration-time curve from baseline to each by time point. For PK endpoints, continuous variables will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. |
| Exploratory assessment -Change from baseline in CNV activity as measured by OCTA. | Baseline upto 5 months | For OCTA assessment, continuous variables will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum; and categorical variables will be presented by dose group with frequency, percentage, and 95% confidence interval. |
| Immunogenicity parameters - ADA formation rate | Baseline upto 5 months | Presence anti-drug antibody (ADA). For immunogenicity assessment, categorical variables will be presented by dose group with frequency, percentage, and 95% confidence interval. |
| Pharmacokinetic parameters - Half-life (T1/2) | Baseline upto 5 months | Half-life by dose level. For PK endpoints, continuous variables will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. |
| Pharmacokinetic parameters - Volume of distribution (Vd) | Baseline upto 5 months | Volume of distribution by dose level. For PK endpoints, continuous variables will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. |
| Pharmacokinetic parameters - Clearance (CL) | Baseline upto 5 months | Clearance by dose level. For PK endpoints, continuous variables will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. |
| Pharmacokinetic parameters - Minimum blood concentration (Cmin) | Baseline upto 5 months | Minimum concentration of drug by dose level. For PK endpoints, continuous variables will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. |
| Pharmacokinetic parameters - Maximum blood concentration (Cmax) | Baseline upto 5 months | Maximum concentration of drug by dose level. For PK endpoints, continuous variables will be presented by dose group with number of subjects, mean, standard deviation, median, minimum, and maximum. |
Countries
South Korea
Outcome results
None listed